Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates
Authors:
- Lang KuhsLKLang Kuhs
- Krystle A.KAKrystle A.
- Carolina PorrasCPCarolina Porras
- John T. SchillerJSJohn T. Schiller
- Ana Cecilia RodriguezARAna Cecilia Rodriguez
- Mark SchiffmanMSMark Schiffman
- Paula GonzalezPGPaula Gonzalez
- Arpita GhoshAGArpita Ghosh
- Yan LiYLYan Li
- Douglas R. LowyDLDouglas R. Lowy
- Aimée R. KreimerAKAimée R. Kreimer
Open Access
- 19 August 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 180 (6) , 599-607
Abstract
Two trials of clinically approved human papillomavirus (HPV) vaccines, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE I/II) and the Papilloma Trial Against Cancer in Young Adults (PATRICIA), reported a 22% difference in vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 2 or worse in HPV-naïve subcohorts; however, serological testing methods and the HPV DNA criteria used to define HPV-unexposed women differed between the studies. We applied previously described methods to simulate these HPV-naïve subcohorts within the Costa Rica HPV16/18 Vaccine Trial and assessed how these criteria affect the estimation of VE. We applied 2 enzyme-linked immunosorbent assay (ELISA) thresholds for HPV16 and HPV18 seropositivity (8 and 7 ELISA units/mL, respectively, for PATRICIA; 54 and 65 ELISA units/mL, respectively, for FUTURE I/II (to approximate the competitive Luminex immunoassay)) and 2 criteria for HPV DNA positivity (12 oncogenic HPV types, plus HPV66 and 68/73 for PATRICIA; or plus HPV6 and 11 for FUTURE I/II). VE was computed in the 2 naïve subcohorts. Using the FUTURE I/II and PATRICIA criteria, VE estimates against cervical intraepithelial neoplasia grade 2 or worse, regardless of HPV type, were 69.0% (95% confidence interval: 40.3%, 84.9%) and 80.8% (95% confidence interval: 52.6%, 93.5%), respectively (P = 0.1). Although the application of FUTURE I/II criteria to our cohort resulted in the inclusion of more sexually experienced women, methodological differences did not fully explain the VE differences.Keywords
This publication has 17 references indexed in Scilit:
- A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old GirlsPLOS ONE, 2013
- A Review of Clinical Trials of Human Papillomavirus Prophylactic VaccinesVaccine, 2012
- Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2012
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccineHuman Vaccines, 2011
- Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa RicaCancer Discovery, 2011
- Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young WomenJNCI: Journal of the National Cancer Institute, 2010
- Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa RicaVaccine, 2008
- Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical LesionsNew England Journal of Medicine, 2007
- Novel Short-Fragment PCR Assay for Highly Sensitive Broad-Spectrum Detection of Anogenital Human PapillomavirusesThe American Journal of Pathology, 1998